{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:05Z","timestamp":1790960765074,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1F1A1070468"],"award-info":[{"award-number":["2020R1F1A1070468"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021M3E5D1A01015176"],"award-info":[{"award-number":["NRF-2021M3E5D1A01015176"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["1711138447"],"award-info":[{"award-number":["1711138447"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["KMDF_PR_20200901_0214"],"award-info":[{"award-number":["KMDF_PR_20200901_0214"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although respiratory infections are common causes of acute respiratory failure (ARF) in patients with myositis-interstitial lung disease (ILD), limited data are available regarding the treatment outcomes by the etiologies of acute exacerbation (AE) of myositis-related ILD (infectious vs. non-infectious). Our study aimed to investigate the treatment outcomes of AE in patients with myositis-related ILD focused on the infectious etiology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single center-based retrospective cohort was performed at Hanyang University Hospital between January 2000 and December 2018. A total of 36 patients with AE of myositis-related ILD were consecutively included. The exposure was the etiologies of AE in myositis-related ILD, and the outcome was in-hospital mortality. The infectious etiology was defined as confirmation of bacteria, virus, or fungus in samples obtained from the respiratory tract.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 36 patients, 17 were diagnosed with infectious AE. The overall in-hospital mortality rate of AE was 47.2%. Although the mortality rate in patients with infectious AE was lower (41.2%) than in those with non-infectious AE (52.6%), this difference was not statistically significant (<jats:italic>p<\/jats:italic> = 0.724). A survival analysis showed no significant difference in mortality between patients with infectious AE versus those with non-infectious AE [risk ratio = 0.78, 95% CI = 0.38\u20131.59].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study showed that infectious AE is an important cause of mortality in patients with myositis-related ILD, showing a similar risk of mortality as non-infectious AE.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.801206","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:08:45Z","timestamp":1646633325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Outcomes of Infectious and Non-infectious Acute Exacerbation of Myositis-Related Interstitial Lung Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Joo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Won","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.rdc.2019.07.006","article-title":"Idiopathic inflammatory myopathies","volume":"45","author":"Vencovsk\u00fd","year":"2019","journal-title":"Rheum Dis Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2020.00012","article-title":"Acute exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies: a retrospective case-control study","volume":"7","author":"Liang","year":"2020","journal-title":"Front Med."},{"key":"B6","unstructured":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis5864\n            FujisawaT\n            SudaT\n            NakamuraY\n            EnomotoN\n            IdeK\n            ToyoshimaM\n          15630726J Rheumatol.322005"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s40674-018-0110-6","article-title":"Myositis-Related interstitial lung diseases: diagnostic features, treatment, and complications","volume":"5","author":"Shappley","year":"2019","journal-title":"Curr Treatm Opt Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1183\/09059180.00000713","article-title":"The role of infection in the pathogenesis of idiopathic pulmonary fibrosis","volume":"22","author":"Molyneaux","year":"2013","journal-title":"Eur Respir Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.chest.2017.03.033","article-title":"The role of infection in interstitial lung diseases: a review","volume":"152","author":"Azadeh","year":"2017","journal-title":"Chest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","article-title":"New myositis classification criteria-what we have learned since bohan and peter","volume":"20","author":"Leclair","year":"2018","journal-title":"Curr Rheumatol Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4046\/trd.2005.58.3.230","article-title":"Normal predictive values of spirometry in Korean population","volume":"58","author":"Choi","year":"2005","journal-title":"Tuberc Respir Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"76129","DOI":"10.18632\/oncotarget.19050","article-title":"Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"190045","DOI":"10.1183\/16000617.0045-2019","article-title":"The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis","volume":"28","author":"Invernizzi","year":"2019","journal-title":"Euro Respir Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fmed.2019.00326","article-title":"Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment","volume":"6","author":"Hervier","year":"2019","journal-title":"Front Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"180061","DOI":"10.1183\/16000617.0061-2018","article-title":"Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit","volume":"27","author":"Huapaya","year":"2018","journal-title":"Eur Respir Rev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.801206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:08:52Z","timestamp":1646633332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.801206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":23,"alternative-id":["10.3389\/fmed.2021.801206"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.801206","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"801206"}}